title: No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment.
abstract: BACKGROUND
  This study tested the hypothesis that statins may reduce left ventricular hypertrophy (LVH) in patients with hypertension and LVH.
  
  
  METHODS
  A prospective randomised open-label study with blinded endpoints assessment was performed in 142 patients. Inclusion criteria were hypertension, left ventricular ejection fraction ≥50% and echocardiographic determined LVH, defined as a left ventricular mass index (LVMI) of ≥ 100 g/m(2) in women and ≥ 116 g/m(2) in males. Patients were randomised between rosuvastatin 20mg once daily vs control. For each patient an echocardiogram and blood samples were obtained. These tests were repeated after 6 months.
  
  
  RESULTS
  Baseline characteristics: mean age was 62 ± 11year and 62 (44%) were male. In both groups, there was a non-significant reduction in LVMI: 118 ± 22 to 111 ± 19 g/m(2) in the control group and 118 ± 21 to 114 ± 22 in the rosuvastatin group (p=0.376 for the comparison between rosuvastatin and control after 6 months). After six months, LDL-cholesterol was reduced from 3.5 ± 1.0 to 2.1 ± 1.2 mmol/L (40% reduction) in the rosuvastatin group and remained unchanged in the control group (3.5 ± 0.9 vs 3.6 ± 0.9 mmol/L. Hs-CRP decreased more with rosuvastatin compared to control (-38% vs -15%, p=0.006) There was no significant reduction in NT-pro-BNP levels after 6 months.
  
  
  CONCLUSIONS
  Rosuvastatin does not reduce LVH despite a large LDL reduction in patients with hypertension and LVH.
authors.forename: R J
authors.initials: RJ
authors.lastname: Folkeringa
authors.forename: C
authors.initials: C
authors.lastname: de Vos
authors.forename: Y M
authors.initials: YM
authors.lastname: Pinto
authors.forename: J
authors.initials: J
authors.lastname: Habets
authors.forename: P W
authors.initials: PW
authors.lastname: De Leeuw
authors.forename: R G
authors.initials: RG
authors.lastname: Tieleman
authors.forename: M H
authors.initials: MH
authors.lastname: Prins
authors.forename: M
authors.initials: M
authors.lastname: Van Dieijen-Visser
authors.forename: H J G M
authors.initials: HJ
authors.lastname: Crijns
mesh_terms: D000368:Aged; D008078:Cholesterol, LDL / Q000097:blood; D023381:Endpoint Determination / Q000379:methods; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium